Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab

Barry, Gerard P.; Tauber, Kate A.; Fisher, Matthew; Greenberg, Scott; Zobal-Ratner, Jitka; Binenbaum, Gil

doi:10.1016/j.jaapos.2019.05.013

Cited by 7 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some research has postulated that anti-VEGF agents have advantages over LPC, including easier administration, rapid action, and superior refractive and anatomical outcomes [ 6 , 8 , 13 , 14 , 18 , 19 ]. However, other studies have reported contrasting findings [ 18 , 20 - 22 ]. Our study revealed a significantly higher rate of regression in the LPC-treated group compared to the IVR-treated group (100% vs. 81%, p<0.05); this contradicts the previous findings reported by Linghu et al [ 23 ].…”

Section: Discussionmentioning

confidence: 91%

“…A higher incidence of retinal detachment was detected following LPC treatment in comparison to IVR (p>0.05). Barry et al reported that ROP treatment with anti-VEGF agents led to superior short-term anatomical outcomes [ 17 , 22 ]. LPC demonstrated a slightly delayed VEGF-lowering effect as laser ablation of the avascular retina requires time to diminish the production of new VEGF.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Intravitreal Ranibizumab and Laser Photocoagulation in the Treatment of Type I Retinopathy of Prematurity in Malaysia: A One-Year Follow-Up Study

Wardati H,

Khadijah,

Nurul-Farhana

et al. 2024

Cureus

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Comparison of Intravitreal Ranibizumab and Laser Photocoagulation in the Treatment of Type I Retinopathy of Prematurity in Malaysia: A One-Year Follow-Up Study

Wardati H,

Khadijah,

Nurul-Farhana

et al. 2024

Cureus

View full text Add to dashboard Cite

“…The results of all the other RCTs (except RAINBOW), and the observational studies, that compared the rates of disease recurrence, disease regression, need for retreatment between IVB, IVR and LPC groups, are displayed in Table 4 [ 5 , 6 , 10 , 13 , 19 , 22 , 29 , 33 , 36 – 40 , 42 , 44 – 46 , 48 – 51 ].…”

Section: Resultsmentioning

confidence: 99%

Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review

et al. 2022

View full text Add to dashboard Cite

Purpose To synthesize existing evidence on adverse events, complications, and unfavorable outcomes of current treatment modalities for treatment-requiring retinopathy of prematurity (TR-ROP). Methods PubMed, Cochrane Central Register of Controlled Trials, Scopus, EMBASE, Trip Database, and the gray literature available were searched. Randomized Clinical Trials and observational studies comparing the adverse events of intravitreal anti-VEGF injections (bevacizumab, ranibizumab, aflibercept, pegaptanib, conbercept) and laser photocoagulation (LPC) as treatment modalities for infants with TR-ROP were included. The main outcomes compared between the two treatment modalities were: 1. Refractive Errors and Biometry Parameters, 2. Adverse events, complications, and unfavorable outcomes, 3. Disease Recurrence/Disease Regression/Need for retreatment, 4. Neurodevelopmental Outcomes. Results Higher quality studies concluded that LPC leads to greater rates of myopia than intravitreal anti-VEGF treatment while the rate of adverse events and of unfavorable neurodevelopmental outcomes is similar. However, there was controversy among the included studies concerning the rate of ROP recurrence between intravitreal anti-VEGF injections and LPC. Conclusion There is need for future primary studies assessing the adverse events of intravitreal anti-VEGF injections compared with LPC as treatment modalities for infants with TR-ROP.

show abstract

“…Due to significant limitations, side-effects, and systemic concerns regarding current treatment modalities [ 28 , 29 , 30 , 31 , 32 , 33 ], several preventative therapies targeting mechanisms within the first phase (vaso-obliteration) of ROP have been explored. One of the most promising and least harmful of which is fish oil [ 34 , 35 , 36 , 37 , 38 , 39 ] and combination fish oil with antioxidants [ 40 , 41 , 42 ], which were shown to decrease neovascularization in humans and animal models.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Glutathione Nanoparticles, CoEnzyme Q10, and Fish Oil for Prevention of Oxygen-Induced Retinopathy in Neonatal Rats

Bashir,

Cai,

Marcelino

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Notch ligands and receptors are important for cell specification and angiogenesis, but their role in oxygen-induced retinopathy (OIR) is not well studied. Delta-like ligand (DLL)-4/Notch inhibits angiogenesis, while Jagged-1/Notch promotes angiogenesis. We tested the hypothesis that early supplementation with antioxidants and/or fish oil curtails severe OIR by inducing DLL-4/Notch and reducing Jagged-1/Notch. Newborn rats were exposed to brief intermittent hypoxia (IH) during hyperoxia, during which they received daily oral supplements of (1) fish oil, (2) coenzyme Q10 (CoQ10) in olive oil (OO), (3) glutathione nanoparticles (nGSH), (4) fish oil + CoQ10, or (5) OO (controls) from birth (P0) to P14. At P14, the pups were placed in room air (RA) until P21, with no further treatment. Oxidative stress, apoptosis, ocular histopathology, and Notch signaling were assessed. Neonatal IH resulted in severe retinal damage consistent with retinopathy of prematurity (ROP). Retinal damage was associated with induced oxidative stress and Jagged-1/Notch signaling, as well as reduced DLL-4/Notch signaling. All treatments reversed these outcomes, but nGSH produced the most beneficial outcomes. Severe OIR promoted the induction of Jagged-1/Notch and curtailed DLL-4/Notch, which was an effect that could be reversed with nGSH supplementation. These findings may indicate a potential alternate pathway for ROP treatment and/or prevention.

show abstract

Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab

Cited by 7 publications

References 14 publications

Comparison of Intravitreal Ranibizumab and Laser Photocoagulation in the Treatment of Type I Retinopathy of Prematurity in Malaysia: A One-Year Follow-Up Study

Comparison of Intravitreal Ranibizumab and Laser Photocoagulation in the Treatment of Type I Retinopathy of Prematurity in Malaysia: A One-Year Follow-Up Study

Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review

Comparison of Glutathione Nanoparticles, CoEnzyme Q10, and Fish Oil for Prevention of Oxygen-Induced Retinopathy in Neonatal Rats

Contact Info

Product

Resources

About